Fresenius Kabi intros generic Ganirelix Acetate injection

Fresenius Kabi is introducing Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.  

The medication is the generic of Organon's Ganirelix Acetate injection

Ganirelix Acetate Injection is available immediately from Fresenius Kabi in 250 mcg/0.5 ml prefilled syringes.

[Read more: Fresenius Kabi launches generic Zemuro]

Ganirelix Acetate Injection is indicated for the inhibition of premature surges in luteinizing hormone, or LH, a chemical in the body that triggers reproductive processes such as ovulation. Ganirelix is used to treat women who are undergoing controlled ovarian hyperstimulation, a fertility therapy.

“We're pleased to expand our Women’s Health portfolio with the introduction of Ganirelix Acetate Injection, which was developed to provide hopeful parents with more choice when navigating in vitro fertilization and other fertility treatments,” said John Ducker, president and CEO of Fresenius Kabi USA.

[Read more: Fresenius Kabi intros generic Tepadina]

Ganirelix Acetate Injection is the third product offering in Fresenius Kabi’s Women’s Health portfolio, which includes Chorionic Gonadotropin for Injection and Progesterone Injection.